Altimmune (ALT) EBITDA Margin Growth (1y) (2011 - 2025)
Powered by 
Analysis
Altimmune (ALT) EBITDA Margin Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -1,651.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,091.00 |
| 10 | Altimmune | 628.10 Mn | 628.10 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 38.62 Mn |
| Sep 30, 2025 | 7.82 Mn |
| Jun 30, 2025 | 7.65 Mn |
| Mar 31, 2025 | 9.96 Mn |
| Dec 31, 2024 | -40.64 Mn |
| Sep 30, 2024 | -48.91 Mn |
| Jun 30, 2024 | -23.48 Mn |
| Mar 31, 2024 | -43.23 Mn |
| Dec 31, 2023 | -204,990.00 |
| Sep 30, 2023 | 123.14 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -8.81 Mn |
| Sep 30, 2022 | -121.66 Mn |
| Jun 30, 2022 | -23.68 Mn |
| Mar 31, 2022 | -5.92 Mn |
| Dec 31, 2021 | -26,710.00 |
| Sep 30, 2021 | -2.04 Mn |
| Jun 30, 2021 | -1.78 Mn |
| Mar 31, 2021 | -144,317.00 |